From major journals, first or last author from the Institute for Cancer Research
Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA(2024) Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival Oncoimmunology, 14(1), 2440967 DOI 10.1080/2162402X.2024.2440967, PubMed 39703053
Pinto R, Vedeld HM, Lind GE, Jeanmougin M(2024) Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework Mol Oncol(in press) DOI 10.1002/1878-0261.13772, PubMed 39696831
Farooqi SJ, Zhao Z, Öjlert ÅK, Thunold S, Juul HV, Bjaanæs MM, Horndalsveen H, Nymoen HMG, Helland Å, Haakensen VD(2024) Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma Front Immunol, 15, 1480183 DOI 10.3389/fimmu.2024.1480183, PubMed 39687621
Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou Get al.(2024) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer Cancer Res(in press) DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396
Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA(2024) Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival Oncoimmunology, 14(1), 2440967 DOI 10.1080/2162402X.2024.2440967, PubMed 39703053
Pinto R, Vedeld HM, Lind GE, Jeanmougin M(2024) Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework Mol Oncol(in press) DOI 10.1002/1878-0261.13772, PubMed 39696831